Literature DB >> 27085781

Exercise-stimulated FGF23 promotes exercise performance via controlling the excess reactive oxygen species production and enhancing mitochondrial function in skeletal muscle.

Dong-Jie Li1, Hui Fu1, Ting Zhao1, Min Ni1, Fu-Ming Shen2.   

Abstract

OBJECTIVE: Physical exercise induces many adaptive changes in skeletal muscle and the whole body and improves metabolic characteristics. Fibroblast growth-factor 23 (FGF23) is a unique member of the FGF family that acts as a hormone regulating phosphate metabolism, calcitriol concentration, and kidney functions. The role of FGF23 in exercise and skeletal muscle is largely unknown yet.
MATERIALS AND METHODS: C57BL/6J mice were exercised on a motor treadmill. Mice serum FGF23 levels; FGF23 mRNA expression in various organs including the liver, heart, skeletal muscle tissue, and thyroid; and FGF23 receptor Klotho mRNA expression were examined using enzyme-linked immunosorbent assay, real-time polymerase chain reaction, and immunoblotting, respectively, after a single bout of acute exercise (60min), exhaustive exercise, and chronic prolonged exercise (60min every day for one week). C57BL/6J mice were injected with recombinant FGF23 (100mg/kg, twice per day, i.p.) or vehicle control (saline) for 3days, and then the exercise performance, reactive oxygen species (ROS), H2O2 production, and mitochondrial functional biomarkers in muscle (gene expression of sirtuin 1, PPAR-δ, PGC-1α and mitochondrial transcription factor A [TFAM], and citrate synthase activity) were assayed.
RESULTS: Three forms of exercise, acute exercise, exhaustive exercise, and chronic exercise, increased serum FGF23 levels. However, only chronic exercise upregulated FGF23 mRNA and protein expression in skeletal muscle. FGF23 mRNA expression in the heart, liver, and thyroid was not affected. FGF23 protein was mainly located in the cytoplasm in skeletal muscle tissue and the localization of FGF23 was not altered by exercise. Exogenous FGF23 treatment significantly extended the time to exhaustion and reduced the exercise-induced ROS and H2O2 production. FGF23 treatment increased the mRNA level of PPAR-δ and citrate synthase activity, but did not influence the mRNA expression of sirtuin 1, PGC-1α, and TFAM in skeletal muscle.
CONCLUSION: These results demonstrate that exercise-stimulated FGF23 promotes exercise performance via controlling the excess ROS production and enhancing mitochondrial function in skeletal muscle, which reveals an entirely novel role of FGF23 in skeletal muscle.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Exercise; FGF23; Mitochondrial function; PPAR-δ; Skeletal muscle

Mesh:

Substances:

Year:  2016        PMID: 27085781     DOI: 10.1016/j.metabol.2016.02.009

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  23 in total

1.  Research advances in metabolism 2016.

Authors:  Nikolaos Perakakis; Olivia M Farr; Dario Tuccinardi; Jagriti Upadhyay; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-11-06       Impact factor: 8.694

Review 2.  Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.

Authors:  Giovanni Lombardi; Mosè Barbaro; Massimo Locatelli; Giuseppe Banfi
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

Review 3.  Musculoskeletal Health in the Context of Spinal Cord Injury.

Authors:  Jillian M Clark; David M Findlay
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

Review 4.  Influence of anaerobic and aerobic exercise on age-related pathways in skeletal muscle.

Authors:  Ignacio Navas-Enamorado; Michel Bernier; Gloria Brea-Calvo; Rafael de Cabo
Journal:  Ageing Res Rev       Date:  2017-05-06       Impact factor: 10.895

Review 5.  Engineered skeletal muscles for disease modeling and drug discovery.

Authors:  Jason Wang; Alastair Khodabukus; Lingjun Rao; Keith Vandusen; Nadia Abutaleb; Nenad Bursac
Journal:  Biomaterials       Date:  2019-08-08       Impact factor: 12.479

Review 6.  Lifestyle Management of Diabetes: Implications for the Bone-Vascular Axis.

Authors:  Silvia Pieralice; Francesca Vigevano; Rossella Del Toro; Nicola Napoli; Ernesto Maddaloni
Journal:  Curr Diab Rep       Date:  2018-08-18       Impact factor: 4.810

7.  The role of RANKL and FGF23 in Assessing Bone Turnover in Type 2 Diabetic Patients.

Authors:  G Niță; O Niță; A Gherasim; L I Arhire; A M Herghelegiu; L Mihalache; C Tuchilus; M Graur
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 1.104

8.  Nicotinic ACh receptor α7 inhibits PDGF-induced migration of vascular smooth muscle cells by activating mitochondrial deacetylase sirtuin 3.

Authors:  Dong-Jie Li; Jie Tong; Fei-Yan Zeng; Mengqi Guo; Yong-Hua Li; Hongbo Wang; Pei Wang
Journal:  Br J Pharmacol       Date:  2018-11-04       Impact factor: 8.739

9.  FGF23, Frailty, and Falls in SPRINT.

Authors:  Anna Jovanovich; Charles Ginsberg; Zhiying You; Ronit Katz; Walter T Ambrosius; Dan Berlowitz; Alfred K Cheung; Monique Cho; Alexandra K Lee; Henry Punzi; Shakaib Rehman; Christianne Roumie; Mark A Supiano; Clinton B Wright; Michael Shlipak; Joachim H Ix; Michel Chonchol
Journal:  J Am Geriatr Soc       Date:  2020-12-01       Impact factor: 5.562

10.  FGF23, a novel muscle biomarker detected in the early stages of ALS.

Authors:  Ying Si; Mohamed Kazamel; Michael Benatar; Joanne Wuu; Yuri Kwon; Thaddaeus Kwan; Nan Jiang; Dominik Kentrup; Christian Faul; Lyndsy Alesce; Peter H King
Journal:  Sci Rep       Date:  2021-06-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.